Colonoscopy is the gold standard for detecting colon cancer, but every year about 50 million people in the U.S. who qualify for a colonoscopy don't get it done, according to the American Cancer ...

It’s good news in the fight against colorectal cancer: A new test can detect the disease with a simple blood draw. But don’t cancel your colonoscopy just yet — that old standby is still more reliable ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based ...

When you buy through links on our articles, Future and its syndication partners may earn a commission. A new blood-based test for colorectal cancer is designed to screen for cancer-related DNA ...

Guardant Health is rated a strong buy, driven by its Shield blood-based colorectal cancer screening and a transformative collaboration with Quest Diagnostics. GH’s Shield test addresses major barriers ...

A groundbreaking blood test for colorectal cancer screening has received approval from the U.S. Food and Drug Administration (FDA), offering the potential to revolutionize early detection for one of ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced an agreement with the Abu Dhabi Public Health Center (ADPHC) to introduce ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered for active-duty service members and ...

Approval demonstrates unique value of Shield test for CRC screening and improves Medicare pricing PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, ...

Shield is a non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the ...